Yazen raises $50M as Verdane takes largest stake in Swedish weight-loss startup
What's the deal? Swedish health startup Yazen has raised US$60.4M in a late-stage round led by Verdane, which becomes its largest shareholder.
What does it do? Yazen offers a weight-loss programme built around the trendy class of weight-loss drugs now driving demand across the sector. The company says it is coming off a record year.
Why now? Growth has cooled from its earlier pace. "This year we see steady growth, but it's not as explosive," chief executive officer Fredrik Meurling told Breakit (translated from Swedish).
What's the endgame? Meurling framed the raise as securing the company's runway, saying it has "strengthened the company for a few years ahead" (translated from Swedish).
The signal: The round sits in the 95th percentile of all-time late-stage venture deals for health startups in Sweden, underscoring investor appetite for companies riding the weight-loss drug wave.
Read more: breakit.se
Image credit: Yazen
